No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".
None.
None.
No insider has filed a notice of proposed sale (Form 144) for iTeos Therapeutics, Inc. in the last 12 months.
No 13F manager reports holding iTeos Therapeutics, Inc..
| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
VT
Vanguard Index Funds
|
$7.68M | 770.6K | 1.74% | 0.00% | June 30, 2025 |
|
IR
iShares Trust
|
$7.41M | 743.3K | 1.68% | 0.01% | June 30, 2025 |
23 more funds behind a free account
See every fund holding iTeos Therapeutics, Inc. and how much of the fund the position is.
Sign up free| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
ON
Oleg Nodelman
5%+ holder
13D · 27.9%
|
10.7M | 24.18% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
|
EC
EcoR1 Capital, LLC
5%+ holder
13D · 27.9%
|
10.7M | 24.18% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
25 more holders behind a free account
See every insider and 5%+ holder of iTeos Therapeutics, Inc..
Sign up freeLoading...